focal (partial onset) epilepsy
Conditions
Brief summary
The responder rate defined as the percent of patients who experience a 50% or greater reduction from baseline in seizure frequency in the Treatment Period compared to placebo
Detailed description
The median percent change from baseline in 28-day focal seizure frequency (focal aware motor with observable component, focal impaired awareness, or focal to bilateral tonic-clonic seizures) compared to placebo, The percent of patients who are seizure free during the last 28 days of the Treatment Period, The percent of patients who are seizure free during the entire Treatment Period
Interventions
Sponsors
Engrail Therapeutics Inc.
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The responder rate defined as the percent of patients who experience a 50% or greater reduction from baseline in seizure frequency in the Treatment Period compared to placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| The median percent change from baseline in 28-day focal seizure frequency (focal aware motor with observable component, focal impaired awareness, or focal to bilateral tonic-clonic seizures) compared to placebo, The percent of patients who are seizure free during the last 28 days of the Treatment Period, The percent of patients who are seizure free during the entire Treatment Period | — |
Countries
Belgium, Germany, Netherlands, Spain
Outcome results
None listed